Kathy V. Turner - Feb 15, 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Senior Vice President
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Kathy V. Turner
Stock symbol
IDXX
Transactions as of
Feb 15, 2023
Transactions value $
-$434,852
Form type
4
Date filed
2/17/2023, 04:04 PM
Previous filing
Feb 16, 2023
Next filing
Apr 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Award $79.5K +1K +13.55% $79.54* 8.38K Feb 15, 2023 Direct
transaction IDXX Common Stock Sale -$510K -1K -11.93% $510.03 7.38K Feb 15, 2023 Direct F1
transaction IDXX Common Stock Options Exercise $795 +10 +0.14% $79.54* 7.39K Feb 16, 2023 Direct
transaction IDXX Common Stock Sale -$5.16K -10 -0.14% $515.58 7.38K Feb 16, 2023 Direct
holding IDXX Common Stock 100 Feb 15, 2023 by spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -1K -21.11% 3.74K Feb 15, 2023 Common Stock 1K $79.54 Direct F3, F4
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -10 -0.27% 3.73K Feb 16, 2023 Common Stock 10 $79.54 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2 The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F3 Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4 Not applicable.